Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Araxes, Janssen in Cancer Drug Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Araxes, Janssen in Cancer Drug Pact

Araxes to receive upfront payment and R&D funding, eligible for royalties

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Araxes Pharma has entered into an exclusive agreement with Janssen Biotech to develop first-in-class therapeutics against a certain target for the treatment of cancer. The drug candidates include a PI3Kdelta/gamma inhibitor, a TORC1/2 inhibitor and a PI3Kalpha inhibitor. 
 
Araxes will advance its program through Phase I to clinical proof-of-concept. Janssen Biotech will then have sole responsibility for the continued development and worldwide commercialization of products arising under the agreement. Araxes will receive an upfront payment and R&D funding and is eligible to receive milestone payments and royalties on worldwide sales, but financial terms were not disclosed.
 
“We are delighted to work with Janssen on a very exciting approach for the treatment of patients with cancer,” said Troy Wilson, president and chief executive officer of Araxes Pharma. “Their sophisticated outlook and capabilities for development of molecularly-targeted therapeutics will enable us to accelerate development of our novel, high-quality small molecules.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics